Mold-Tek Packaging Ltd

- For the financial year ending March 2024, the company borrowed only INR 40 crores but invested INR 140 crores, using working capital funds for investments rather than raising new debt extensively. - Current working capital utilization is significantly below drawing power, indicating no immediate need for additional funds. - Capital expenditure for the current year is expected around INR 70 crores, mainly for Pharma segment investments and balancing equipment for IML and Panipat thin wall plants. - No explicit mention of fresh fundraising through debt or equity in the near term. - Future capex and fundraising needs depend on Pharma segment growth; if Pharma grows significantly, additional investments may be required. - Review of capacity expansion expected around Q3 FY '25, which may influence future fundraising decisions. - Overall, no clear indication of immediate plans for new debt or equity fundraising as of May 31, 2024.

- Current year capex planned is around INR 15 crores for the new smaller Mahad plant, with land already acquired. - Additional investments this year are mainly for Pharma expansion, balancing equipment mainly for IML, and Panipat thin wall plant. - Estimated total investment for the current year could be around INR 70 crores, less than last year's INR 140 crores. - Capacity additions are based on need; significant capacity was added in the last 2-3 years, with new capacities set for production this year. - Potential capacity expansion in Pharma may be considered around Q3 depending on demand and progress. - Consolidation and centralization of printing and die-cutting operations at Sultanpur to improve efficiency and reduce costs planned within 6 months. - Strategic focus on Pharma and Food & FMCG segments expected to drive future investments.

- Volume growth guidance for FY '25 is around 12% to 14%, driven mainly by the addition of Aditya Birla Group (ABG) plants contributing 7% to 10% growth. - Paint segment expected to grow at 2% to 5%, with new clients in IML contributing additional growth. - Food & FMCG volumes targeted for 20% growth, supported by new products like sweet boxes from Panipat plant starting July-August. - Qpack volumes expected to grow 30% to 40% plus, with continued strong demand. - Pharma segment to grow rapidly, with FY '25 revenues expected around INR 20 crores, potentially doubling the next year due to new client onboarding and faster product development. - Consolidation and capacity optimizations to improve EBITDA above 40%, supporting overall growth. - Long-term strategy emphasizes growth in Pharma and Food & FMCG, while maintaining Paint and Lubes with focus on value-added products like IML.

- Volume growth is expected in double digits, with guidance around 12% to 14% for FY 2025. - Addition of Aditya Birla Group (ABG) plants alone is expected to contribute 7% to 10% growth. - Pharma segment is seen as a key growth driver, with current capacity utilization expected to reach 70%-80% by Q3 FY25, targeting INR20 crore turnover this year and doubling next year. - EBITDA margin is anticipated to improve beyond 40% in FY25, up from 37.7% in FY24, driven by better capacity utilization, improved product mix (more Qpack, Food & FMCG, pharma), and operational efficiencies. - The company is targeting a 15%+ volume growth overall, with Food & FMCG segment aiming for 20% growth and Qpacks expected to grow 30%-40%. - Continuous capacity additions, especially in pharma and thin wall packaging, support medium to long-term profitability expansion.

- Mold-Tek Packaging has received multiple big inquiries with several potential clients visiting and evaluating their products. - Some clients have made decisions based on initial indications, and capacity is expected to be almost fully utilized within about 6 months after sample evaluations and stability tests. - Commercial production in pharma started around February; capacity utilization is targeted to reach 70%-80% by Q3 of the financial year. - Expected pharma turnover is INR 2-3 crores per month starting mid-year, with a full-year target close to INR 20 crores, potentially doubling next year. - Onboarding of clients is progressing, and expansion decisions for pharma capacity will be revisited by Q3, based on demand. - The company is confident that the addition of new plants (especially for Aditya Birla Group) and pharma segment growth will significantly add to future orderbook volumes.